Kuala Lumpur, January 25, 2017 – CCM Pharmaceuticals Sdn Bhd (CCMP), a subsidiary of CCM Duopharma Biotech Berhad (CCMD), and Biocon Sdn Bhd (a subsidiary of Biocon Ltd) have been awarded a Letter of Award (LOA) by the Ministry of Health (MOH) to supply Human Insulin to all government hospitals and clinics valued at RM300 million for three years until December 1, 2019.

In 2012, CCMP inked a strategic partnership with Biocon, Asia’s leading biopharmaceutical enterprise, giving the Company exclusive license and distribution rights to market, sell and distribute a range of insulin products in Malaysia, Singapore and Brunei.